Skip to content
Catalyst brief · Phase 3 readout · 26 days

Ralinepag: Ralinepag in PAH

United Therapeutics · $UTHR · built 19 Nov 2026 from 15 sourced facts · open on the radar

Analyst desk

Five AI analysts read the facts below. Each sentence shows the facts it rests on.

Trial design

  • The trial's open-label design and single study arm may impact the convincingness of the results, as there is no blinding or comparison group to measure against. F4 F6
  • The main goal of measuring treatment-emergent adverse events over up to 6 years focuses on safety and tolerability, which is an important aspect of the trial. F3 F5
  • The large planned enrollment of 1,000 patients could provide a more robust understanding of the treatment's effects, but the lack of randomization and blinding may still affect the results' reliability. F2 F4

Base rates

  • Historically, 62.1% of Phase 3 programmes in cardiovascular and metabolic moved on to a regulatory filing, which is an industry average and not a forecast for this trial. F11
  • UTHR has a record of delaying trials, with 40% of its active Phase 2 and 3 trials having their dates moved back by more than 6 months. F12
  • Past result-day moves are not provided, but the company's cash position and operating cash flow may be relevant to consider. F13 F14

Filings

  • There have been no open-market insider purchases or unplanned sales reported in the last 90 days. F15
  • The primary completion date of the Ralinepag trial is estimated to be Dec 2026, which is close to the current date, but there is no information about FDA dates or letters. F8

The case for

  • The trial's focus on safety and tolerability over up to 6 years is a key aspect, and the large planned enrollment of 1,000 patients could provide a robust understanding of the treatment's effects. F2 F3 F5

The case against

  • The trial's open-label design and single study arm may impact the convincingness of the results, which could lead to a failed trial or delayed reporting of results. F4 F6
  • UTHR has a record of delaying trials, with 40% of its active Phase 2 and 3 trials having their dates moved back by more than 6 months, which increases the likelihood of this trial reporting late. F12
  • The large planned enrollment of 1,000 patients and long measurement period of up to 6 years may pose challenges to the trial's timely completion, potentially leading to delays or a failed trial. F2 F5
  • The lack of randomization and blinding in the trial design may affect the results' reliability, which could contribute to a failed trial or delayed reporting of results. F2 F4

Open questions

  • Will the open-label design and lack of a comparison group significantly impact the convincingness of the trial results?
  • Can the large planned enrollment of 1,000 patients offset the potential reliability issues due to the trial design?
  • Will UTHR's history of delaying trials affect the timing of the Ralinepag trial readout?

7 AI sentences were removed by the fact check.

The facts

The trial

  • F1Ralinepag is a Phase 3 trial of Ralinepag in PAH, sponsored by United Therapeutics (UTHR). source ↗
  • F2The trial plans to enrol 1,000 patients. source ↗

What counts as success

  • F3Main goal as written in the registry: Number of subjects with treatment-emergent adverse events [Safety and Tolerability]. source ↗
  • F4Blinding: open label (no blinding). source ↗
  • F5The main goal is measured over: Up to 6 years. source ↗
  • F6Number of study arms: 1. source ↗

When

  • F8The registry gives the primary completion date as Dec 2026 (an estimate), which is 26 days from 19 Nov 2026. source ↗
  • F9That date is 27.0 months later than the date first registered for this trial (Sep 2024). source ↗
  • F10The DataCutoff timing model estimates this trial finishes close to its registry date. source ↗

Recruitment

Base rates

  • F11Historically 62.1% of Phase 3 programmes in cardiovascular and metabolic (the group DataCutoff files this trial under) moved on to a regulatory filing (BIO / Informa / QLS study of 2011 to 2020). This is an industry average, not a forecast for this trial.
  • F1240% of UTHR's active Phase 2 and 3 trials have moved their date back by more than 6 months. source ↗

Money, insiders and FDA

  • F13UTHR reported $2.1B in cash and short-term investments as of 30 Sep 2026 (10-Q). source ↗
  • F14UTHR's operating cash flow was positive over the last 12 months, so it is not burning cash. source ↗
  • F15No open-market insider purchases or unplanned sales were reported in the last 90 days. source ↗

How this page is made: the facts come straight from the trial registry, SEC filings and FDA records, each with its link. AI analysts may only restate those facts, and any sentence with a number that is not in a cited fact is removed before publishing. How our models work. Dates are company-reported estimates. Information only, not investment or medical advice.